Malignant Neoplasms

Inhibrx to Seek FDA Approval in 2026 After Strong Phase 2 Data for Bone Cancer Drug Ozekibart

1 month ago talkbio0Tagged Anti-DR5 Agonistic Monoclonal Antibody INBRX-109, Biological Factors, Chondrosarcoma, Infrequent, Inhibrx, Liver, Malignant Bone Neoplasm, Malignant Neoplasms, ozekibart, Progression-Free Survival, Receptors, Tumor Necrosis Factor, Member 10b, Submission, Toxicity aspects, United States Food and Drug Administration

Inhibrx; FDA submission; ozekibart; INBRX-109; chondrosarcoma; bone cancer; phase 2 clinical trial; progression-free survival; death receptor 5; biologics license application; rare cancer; liver toxicity

Iambic’s AI-Designed HER2 Inhibitor IAM1363 Shows Early Anti-Tumor Activity in Heavily Pretreated Patients

1 month ago talkbio0Tagged AI-designed drug, brain-penetrant, Clinical Trials, IAM1363, Iambic Therapeutics, Malignant Neoplasms, Protein-tyrosine kinase inhibitor, Substance with human epidermal growth factor receptor 2 inhibitor mechanism of action (substance)

Iambic Therapeutics; AI-designed drug; IAM1363; HER2 inhibitor; cancer; clinical trial; Phase 1/1b; ESMO 2025; brain-penetrant; tyrosine kinase inhibitor

Eli Lilly to Invest Over $1 Billion to Expand Manufacturing Footprint in India

2 months ago talkbio0Tagged Alzheimer 's, Autoimmune, contract manufacturing, Diabetes, eli lilly, expansion, Hyderabad, India, Malignant Neoplasms, Manufacturing, Obesity

Eli Lilly; India; manufacturing expansion; contract manufacturing; Hyderabad; pharmaceuticals; obesity; diabetes; Alzheimer’s; cancer; autoimmune

Zymeworks Halts Development of ZW171 T-cell Engager After Phase 1 Trial Assesses Benefit-Risk Profile

3 months ago talkbio0Tagged benefit-risk profile, Clinical Trials, Dose-Limiting, Drug Development, Malignant Neoplasms, mesothelin, T-Cell engager, Toxicity aspects, ZW171, Zymeworks

Zymeworks; ZW171; T-cell engager; mesothelin; cancer; clinical trial; drug development; benefit-risk profile; dose-limiting toxicity

Bristol Myers Squibb Signs $11B Deal With BioNTech for Bispecific Cancer Antibody BNT327, Surpassing Recent Merck and Pfizer Moves

6 months ago talkbio0Tagged Antibodies, Bispecific, BioNTech, biotech partnerships, BNT327, immuno-oncology, Malignant Neoplasms, Myers, PD-L1, Solid Neoplasm, squibb, Vascular Endothelial Growth Factor A

Bristol Myers Squibb; BioNTech; BNT327; bispecific antibody; immuno-oncology; cancer; PD-L1; VEGF-A; solid tumors; biotech partnerships

Genentech Bets Again on Orionis With Potential $2B+ in Crowded Molecular Glue Space

6 months ago talkbio0Tagged Allo-Glue platform, Drug Discovery, genentech, Malignant Neoplasms, molecular glue, Neoplasms, Orionis Biosciences, Partnership, protein degraders

Genentech; Orionis Biosciences; molecular glue; oncology; drug discovery; cancer; partnership; biotech; protein degraders; Allo-Glue platform

Boehringer hopes to be perfect fit for Tessellate’s lead cancer programme

7 months ago talkbio0Tagged ALT-positive, Boehringer, cellular targeting, Ingelheim, Malignant Neoplasms

Malignant Neoplasms, Boehringer, ALT-positive, Ingelheim, cellular targeting

Illumina and Tempus look beyond cancer in new AI-driven genomics deal

7 months ago talkbio0Tagged Artificial Intelligence, Cardiology discipline, Genetic Profile, Genomics, High-Throughput Nucleotide Sequencing, Illumina, Immunology, Malignant Neoplasms, Market, Neurology speciality, Partnership

Illumina, Genomics, Partnership, High-Throughput Nucleotide Sequencing, Malignant Neoplasms, Artificial Intelligence, Cardiology discipline, Neurology speciality, Immunology, Genetic Profile, Artificial Intelligence, Market

Pharma Ads Make Waves at Super Bowl 2025: Pfizer Wins Hearts, Hims & Hers Drives Engagement

10 months ago talkbio0Tagged Awareness, Dosage Forms, Health care facility, likeability, Malignant Neoplasms, Pfizer, Super Bowl 2025, Viewer Device, Weight-Loss Agents

Super Bowl 2025, pharmaceutical advertising, Pfizer, Hims & Hers, ad likeability, viewer engagement, healthcare marketing, cancer awareness, weight loss drugs

Biotech IPOs Kick Off 2025: Ascentage Pharma Raises $126M, Aardvark Therapeutics Files for IPO

10 months ago talkbio0Tagged Ascentage, biotech, Drug Industry, IPOs, Malignant Neoplasms, Obesity, Order Tubulidentata (organism), Pharma

Biotech IPOs, Ascentage Pharma, Aardvark Therapeutics, Cancer Treatment, Obesity Treatment, Pharmaceutical Industry